Good morning, everyone. Another busy day is on the way. We can tell because the shortest of short people raced out the door for the bus to the local schoolhouse and Mrs. Pharmalot is indulging us by brewing yet another cup of stimulation in the coffee kettle. All of which means it is time to get cracking. So, as always, here are some items of interest to help you along. Hope you conquer the world today and, of course, keep us in mind for juicy tips …
Valeant Pharmaceuticals was sued by former Sprout Pharmaceuticals investors who claim the drug maker botched the marketing of the Addyi female libido pill after acquiring it in a $1 billion buyout last year, Bloomberg News reports. The lawsuit claims Valeant violated terms of the deal by overcharging for Addyi and failed to make promised investments to market the drug, shortchanging them former Sprout shareholders on royalty payments.
Meanwhile, Valeant is exploring a sale of its eye-surgery equipment business for perhaps $2.5 billion as part of an effort to unload assets and pare $30 billion in debt, the Wall Street Journal reports. Earlier in the week, the drug maker was reportedly talking to Takeda Pharmaceuticals about selling its Salix unit for about $10 billion. While some investors are buoyed, the potential deals underscore the magnitude of the problems that Valeant faces.
About the Author Reprints
A month’s supply of Viagra costs $900 without insurance. A month’s supply of Addyi costs $800. Based on parity alone the cost is defensible. The difference is that the former actually works.
Spot the nonsense in this text:
“The problems relate to thrombosis, or blood clots, with two thromboembolic events and two cases of thrombotic microangiopathy. Deutsche Bank analyst Richard Parkes believes the problems suggested patients were still experiencing breakthrough bleeds”